Just the other day, on Saturday, I ran down a pot stock “triple play” that offers investors a low-risk, easy-to-buy entry point into the fantastically lucrative world of weed investing.
These “pick-and-shovel” companies consist of some of my earliest, most prescient pot stock recommendations ever. Some of them are even included in the massive Roadmap to Marijuana Millions model portfolio my paid-up subscribers can access.
So it should come as no surprise that I hold these picks pretty close to the vest, watching them constantly.
One of the cornerstone picks there, a cannabis biotech that’s returned high double- and triple-digit gains for folks following along, got some incredible news earlier this week.
It’s a development so fresh it didn’t make it into my roundup, so let me fill you in now.
The Company That Moved First and Never Looked Back
I’ve talked a lot about “first-mover advantage” in my investing research, and it works just as well for entire companies as it does for regular investors.
Case in point: Cambridge, UK-based GW Pharmaceuticals Inc. was the first biotech to be awarded a license to grow cannabis for legal, medical research from the UK’s Home Office, back in the nineties.
That’s one of the reasons why GW was the first biotech to bring a cannabis-derived medicine, Sativex, to market as a U.S.- and EU-approved treatment for chronic pain, spasticity, overactive bladder, and multiple sclerosis.
Sativex’s approval helped put GW Pharmaceuticals and the entire medical cannabis nexus “on the map,” as it were, for the nascent weed-investing niche. The peak gains have been terrific, more than 241% since my very first recommendation in early 2014.